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Background: Over the last decade, an increasing number of studies have been published on the use of amyloid-β (Aβ)
PET imaging with different 18F-radiopharmaceuticals for clinical characterization of Alzheimer’s disease (AD) in different
stages. However, distinct study cohorts and different quantification techniques allow only for an indirect comparison
between the different tracers. Thus, the aim of this study was the direct intra-individual in vivo comparison of
different Aβ-targeted radiopharmaceuticals for PET imaging, including the newly developed agent [18F]FIBT.
Methods: A small group of four animals of a well-characterized APP/PS1 transgenic (tg) mouse model of AD
and gender-matched control (ctl) animals underwent a sequential and standardized PET imaging regimen for
direct comparison of [18F]FIBT, [18F]florbetaben, and [11C]PiB. The quantitative PET imaging data were cross-validated
with the cerebral Aβ plaque load as quantified ex vivo on histological sections.
Results: We found that FIBT (2-(p-methylaminophenyl)-7-(2-[18F]fluoroethoxy)imidazo[2,1-b]benzothiazole) compares
favorably to florbetaben as a high-contrasting PET radiopharmaceutical for imaging Aβ pathology. The excellent
pharmacokinetics of FIBT in combination with its high-binding affinity towards Aβ resulted in feasible high-contrast
imaging of Aβ with high global cortex to cerebellum standard uptake value ratio (SUVR) in 24-month-old tg mice
(tg 1.68 ± 0.15 vs. ctl 0.95 ± 0.02). The SUVRs in transgenic versus control animals (SUVRtg/SUVRctl) for FIBT (1.78 ± 0.16)
were similar to the ratios as observed in humans (SUVRAD/SUVRctl) for the established gold standard Pittsburgh
compound B (PiB) (1.65 ± 0.41).
Conclusions: This head-to-head PET tracer comparison study in mice indicated the good imaging properties of
[18F]FIBT, such as high initial brain uptake, fast clearance of the brain, and high binding affinity towards Aβ as
directly compared to the established amyloid tracers. Moreover, the preclinical study design is recommendable
for reliable assessment and comparison of novel radiopharmaceuticals.
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Amyloid-β (Aβ) PET has become an important research
biomarker for diagnosing and differentiating neurode-
generative disorders, in particular Alzheimer’s disease
(AD). In the last decade, major efforts to develop and
assess radiopharmaceuticals for early visualization and* Correspondence: b.yousefi@tum.de
1Department of Pharmaceutical Radiochemistry, Technische Universität
München, Walther-Meißner-Str. 3, 85748 Garching, Germany
Full list of author information is available at the end of the article
© 2015 Hooshyar Yousefi et al.; licensee Spring
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origquantification of Aβ deposits with PET have been re-
ported [1-3]. These endeavors were related to the
amyloid cascade hypothesis which assumes that fibril-
lar Aβ is one of the key pathogenic hallmarks of AD
[4-6], therefore, it has been depicted as major target
for non-invasive diagnosing of AD. They have resulted
in a variety of newly developed radiopharmaceuticals
which have been assessed in preclinical and clinical
studies [7-10]. Currently, three 18F-labeled PET radio-
pharmaceuticals for Aβ have been evaluated in clinicaler. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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Food and Drug Administration (FDA) and by the
European Medicines Agency (EMA): flutemetamol
[11,12], florbetaben [13-15], and florbetapir [16-24]. At
least two other tracers are already undergoing clinical
investigation [25,26]. In our lab, a new series of Aβ ligands,
imidazo[2,1-b]benzothiazole (IBT), has been developed
inspired by positive imaging results obtained in the
IMPY and Pittsburgh compound B (PiB) studies. The
IBT structural motifs share features with IMPY and
PiB. Furthermore, it also allows stable 18F-fluorination.
Our aim was to develop a more sensitive Aβ ligand
that is easy to synthesize and therefore allows early and
practicable detection of amyloid deposition [25,27,28].
With several 18F-labeled tracers competing, compara-
tive conclusions are of high interest. However, most of
the published studies so far have relied on different meth-
odologies and cohorts, and a direct comparison and rank-
ing in a clinical setting is challenging for their different
characteristics [29]. These limitations draw the attention
to preclinical approaches for a direct intra-individual
in vivo comparison of different 18F-labeled Aβ tracers.
Alongside tracer development advances subsequent to
the application of PiB in a clinical setting [30], Aβ PET
imaging was advanced with more sophisticated detection
modes and highly sensitive detectors combined with
powerful reconstruction and quantification algorithms
[31]. In addition, several transgenic animal models of
AD have been established for preclinical evaluation of
experimental treatments [32-34,10]. Aβ PET imaging
in transgenic mouse models of AD is a powerful tool
to assess Aβ tracer properties in vivo [27,35-38]. How-
ever, recent publications made it clear that the type of
mouse model seems to play a crucial role as they differ
in extent and type of Aβ pathology [39,35]. A new
APP/PS1 transgenic mouse model of AD, expresses
mutant forms of human amyloid precursor protein
(APP) and presenilin-1 (PS1), was characterized [33] in
collaboration with our group for its application in Aβ im-
aging [40] and usage for the evaluation of new Aβ ligands
[25,27,40]. For this mouse model, a linear relation-
ship of Aβ plaque pathology and PiB PET signal was
observed [41].
In the current study, we employed this APP/PS1 mouse
model for a direct comparison of two established and one
newly developed Aβ PET tracer (Scheme 1). Among theScheme 1 Chemical structure of the three Aβ radiopharmaceuticals u18F-labeled Aβ PET radiopharmaceuticals, [18F]florbetaben
has shown good sensitivity and specificity for the detection
of AD [42]. Hence, [18F]florbetaben was selected as refer-
ence 18F-radiopharmaceutical and compared with a prom-
ising in-house developed Aβ PET tracer [18F]FIBT [25,27]
and the 11C-labeled gold standard [11C]PiB. In vivo small
animal PET imaging and ex vivo validation experiments
were carried out for ranking the tracers.
In order to estimate the translational value of the pre-
clinical results, we compared [11C]PiB standard uptake
value ratio (SUVR) values from our APP/PS1 and con-
trol mice with human [11C]PiB SUVR values from
20 AD patients and 15 healthy elderly volunteers.
Methods
Animals
Animal experiments were carried out with the approval
of the institutional animal care committee (Regierung
von Oberbayern, München, Germany) and in accordance
with the German Animal Welfare Act. Animal hus-
bandry followed the regulations of the European Union
(EU) guideline no. 2010/63. All imaging experiments were
performed with male mice: four homozygous APP/PS1 mice
((B6;CB-Tg(Thy1-Psen1*M146V/Thy1-APP*swe)-10Arte),
TaconicArtemis GmbH, Cologne, Germany) on a congenic
C57BL/6 J genetic background and three age-matched con-
trol mice (C57BL/6 J). Mean age and mean weight: 23.8 ±
0.4 months and 33.3 ± 3.2 for APP/PS1 mice (tg) and 24.6 ±
0.4 months and 38.8 ± 2.6 g for C57BL/6 J control mice
(ctl), respectively. For biodistribution studies, BALB/c mice
were obtained from Charles River Laboratories, Sulzfeld,
Germany.
Human subjects
Human data comes from preexisting studies at the
Department of Nuclear Medicine with subjects who
were recruited from the outpatient memory clinic of the De-
partment of Psychiatry at the Technische Universität
München (TUM). They had been referred for the diag-
nostic evaluation of cognitive impairment by general
practitioners, neurologists, psychiatrists, or from other
institutions. They underwent a standardized diagnostic
protocol. All examinations were part of their routine
check-up in the course of the evaluation of the pa-
tient’s neurodegenerative disorders. The psychometric
workup was based on the Consortium to Establish ased in this study.
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which includes the Mini-Mental-State Examination
(MMSE). All patients provided a written informed con-
sent regarding the scientific evaluation of their data.
Radiosynthesis
All chemicals, solvents, and materials were purchased
and directly used without further purification. [18F]flor-
betaben (8% ± 2% radiochemical yield (RCY) and 98%
radiochemical purity) [43,44], [18F]FIBT (20% ± 4% RCY
and 98% radiochemical purity) [25], and [11C]PiB (26%
± 5% RCY and 98% radiochemical purity) [45-47,27]
were synthesized following already published proce-
dures. Analytical HPLC was performed using either a
Chromolith RP-C18e (4.6 × 100 mm; Merck, Dramstadt,
Germany) eluted with a mixture of acetonitrile/0.1-M
ammonium formate (MeCN content between 27.5% and
50%) at a flow rate of 5 mL/min or a Nucleosil 100, CN
4.6 × 250 mm reverse phase column, particle size 5 μm
(CS-Chromatographie, Langerwehe, Germany) eluted
with acetonitrile/0.1-M ammonium formate (MeCN
content between 40% and 60%). Both chromatography
systems were fitted with a UV detector (Sykam Model
S3210 set at 254 nm; Sykam, Fürstenfeldbruck,
Germany). Radiotracers had comparable specific activ-
ities of ≥18 GBq/μmol.
Lipophilicity (log Doct/PBS) measurements
Lipophilicity of the employed compounds was deter-
mined by a conventional partition method between 1-
octanol and phosphate buffered saline (PBS), pH 7.4.
The 1-octanol was saturated with PBS before use.
Briefly, the no-carrier-added tracers, contained in
0.2 mL PBS, were added 0.2 mL of 1-octanol in a 1.5-
mL polypropylene Eppendorf vial. The vial was sealed
and vigorously shaken at room temperature for 5 min.
The mixture was then centrifuged at 3,000 g for 10 min.
A 100 μL aliquot from each of the two phases was
drawn and their radioactivity content was determined in
a NaI (Tl) well-type detector. The log Doct/PBS was
calculated as follows: log Doct/PBS = log (radioactivity
concentration in the 1-octanol phase/radioactivity con-
centration in the PBS phase). The reported values repre-
sent the mean of six independent measurements.
Brain uptake studies of FIBT, florbetaben, and PiB in
BALB/c mice
Ex vivo brain uptake studies were performed in male
BALB/c mice (mean ± SD body weight: 23 ± 2 g). Mice
were injected via lateral tail vein with 4 to 6 MBq of
high specific activity (≥11 GBq/μmol) [18F]FIBT,
[18F]florbetaben, and [11C]PiB contained in 0.1 to
0.15 mL of a solution of isotonic phosphate buffered sa-
line. Groups of mice were killed at 5 and 30 min p.i.Radioactivity of weighted brain samples was measured in
a γ-counter (Wallac 1480-011 Automatic Gamma Coun-
ter, PerkinElmer, Waltham, MA, USA). Data are
expressed as percent of the injected dose per gram tissue
(% I.D./g; mean ± SD, N = 5).
PET imaging
Small animal PET
Inhalation anesthesia with isoflurane was used and the
eyes of the animals were protected with dexpanthenol
eye ointment. Anesthesia was initiated 15 min ahead of
experiments by placing the animal in a cage ventilated
with oxygen (3.5 L/min) containing 3% isoflurane.
Throughout the experiments, anesthesia was maintained
by adjusting the isoflurane content (0.6% to 2%) to
ensure a respiratory rate in the range 80 to 100/min. For
i.v. injection, we inserted a tailored catheter into the lat-
eral tail vein. Simultaneously with a slow bolus injection
of 50 to 200 μL of tracer solution, we started the PET
with scan duration of 45 min in 3D list mode on a Sie-
mens Inveon system (axial field-of-view of 12.7 cm with
a bore diameter of 12 cm, approximately 1.4 mm full-
width-at-half-maximum spatial resolution; Siemens
Healthcare, Erlangen, Germany). After tracer injection,
we flushed the catheter with 50 to 100 μL of isotonic so-
dium chloride solution. During the scan, a heating pad
prevented hypothermia. The radioactivity in the syringe
was measured immediately before and after injection
with a Capintec CRC® 15R (Capintec Inc, 6 Arrow Road
Ramsey, NJ, USA) dose calibrator.
Scanning regimen of PiB, FIBT, and florbetaben
Measurements of all three tracers in each animal were
performed within a time period of 16 days to guarantee
for comparable underlying neuropathology among the
PET scans (Table 1).
MR imaging of mice
A brain MR scan was performed on all tg and ctl mice
within 0 to 6 days after PET scans. Throughout the MR
scan, animals were under continuous 1.0% to 1.8% iso-
flurane anesthesia with 2 L/min oxygen flow. Eyes were
protected with dexpanthenol ointment. Hypothermia
was prevented with a heat storing gel pack (ColdHot,
3 M, Saint Paul, MN, USA) preheated in a microwave
oven.
We acquired T1 weighted brain images using a 3D
turbo gradient echo (3D-TFE) sequence with an inver-
sion pre-pulse (TR: 12 ms, TE: 3.9 ms, TI: 800 ms, TFE
factor: 120, flip angle: 8°, NSA: 12, acquired matrix M ×
P: 248 × 120, partitions: 60, FOV: 64 × 32 × 16 mm, reso-
lution: 0.26 × 0.27 × 0.26 mm, reconstructed resolution:
0.13× 0.13 × 0.13 mm) on a Philips Achieva 1.5 T clinical
Table 1 Scanning regimen of [11C]PiB, [18F]FIBT, and [18F]florbetaben
Group Number Tracer 1 Injected dose
(MBq)
Δt to next scan
(days)
Tracer 2 Injected dose
(MBq)




APP/PS1 1 Florbetaben 12.2 5 FIBT 9.4 3 PiB 8.9
2 Florbetaben 8.9 5 FIBT 6.6 3 PiB 10.7
3 Florbetaben 9.2 13 FIBT 16.3 3 PiB 19.5
4 Florbetaben 13.4 13 FIBT 13.0 3 PiB 16.7
Ctl 1 Florbetaben 10.2 5 FIBT 10.6 3 PiB 14.3
2 Florbetaben 7.9 5 FIBT 8.0 3 PiB 12.5
3 Florbetaben 4.6 13 FIBT 14.0 3 PiB 18.4
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time was 46 min 11 s.Mouse PET and MRI
Based on our experience, variance of macroscopic brain
anatomy is very low across mice with the same genetic
background. Therefore, the creation of a MRI template
was done by manual co-registration of all MR images
based on prominent brain structures and the overall cor-
tical contour and calculation of a mean image (Pmod
3.3, Pmod Technologies, Zurich, Switzerland). Structures
outside of the brain were not considered in the manual
co-registration process. Two major volume-of-interests
(VOIs) were defined on the MRI template, one compris-
ing the full cortex including hippocampus, the other
comprising the full cerebellum. The same VOIs were
then used for reading out co-registered PET data of a
mean image of the final 10 min of the scan (minute 36
to 45). The VOIs were chosen based on previous find-
ings in a voxel-based analysis of cerebral PiB uptake and
its correlation with the underlying Aβ pathology in this
mouse model [41]. PET data was normalized and cor-
rected for decay and dead time. The images were recon-
structed by means of filtered back-projection (FBP),
using a ramp filter with a cutoff at the Nyquist frequency
into 45 frames (45 × 60 s). The image volume consisted
of 128 × 128 × 159 voxels, each of a size of 0.78 × 0.78 ×
0.80 mm. The PET images were manually co-registered
with the MRI template. This was done by using the
wash-in phase of the tracer to identify the brain contour
for alignment with the MRI template. We scaled the
PET images to percentage of injected dose per cubic
centimeter. We then applied these VOIs to the co-
registered PET images and exported the VOI values to
Microsoft Excel 2010 in order to calculate cortex +
hippocampus-to-cerebellum ratios (further referred to as
PET ratios).
We tested the tg/ctl ratios for significance. First, we per-
formed a one-way ANOVA between the three groups
showing significance. Post hoc Bonferroni corrected t-tests
thresholded at p < 0.05 revealed that the significantdifference is due to group differences between PiB and
florbetaben and FIBT and florbetaben.
Brain dissection and tissue section preparation
Immediately after the third PET scan, each animal was
sacrificed per cervical dislocation. The skull was dis-
sected and opened mid-sagittally with fine scissors. The
brain was carefully removed, halved in the left and right
hemisphere and frozen with fine crushed dry ice and
stored in a refrigerator at −80°C. For histological stain-
ing, the right hemisphere of each animal was thawed,
para-sagittal halved and paraffinated. The resulting par-
affin blocks were then cut with a thickness of 5 μm and
mounted 3 sections per glass slide.
Thioflavin S staining and microscopy
Before staining, the sections were deparaffinated and
rehydrated. The sections were then incubated in a 1%
(1 g per 100 ml water) solution of Thioflavin S (TfS)
(T1892, Sigma-Aldrich, St. Louis, MI, USA) for 30 min.
The sections were then washed with water three times
for 2 min, 80% ethanol for 6 min, washed again with
water and cover slip mounted with VectaShield as
mounting medium (H-1500 with DAPI, Vector Labora-
tories Inc., Burlingame, CA, USA). The slides were
stored at 4°C until microscopic image acquisition. Digital
images were acquired with an automated whole-slide-
scanner (Mirax Scan, Carl Zeiss MicroImaging GmbH,
Jena, Germany) using filter sets for DAPI, GFP, and
Texas Red. The DAPI (contained in the mounting
medium) fluorescence was used by the scanner to set
the optical focus, GFP contained the specific signal of
Thioflavin S, and Texas Red delivered unspecific fluores-
cence such as tissue auto-fluorescence. Images were pre-
processed with Photoshop CS4 in order to define (blue-
channel) the cortex and hippocampus as regions of
interest for plaque load analysis.
Histological plaque load analysis
To measure the relative plaque load in a region of inter-
est (ROI) of each section, we used the AcapellaTM
Table 2 Log Doct/PBS values of tested compounds (mean ± SD; N = 6)
Tracer [11C]PiB [18F]FIBT [18F]Florbetaben
Log Doct/PBS 1.50 ± 0.11 1.92 ± 0.06 1.58 ± 0.13
p [18F]FIBT > [11C]PiB* [18F]FIBT > [18F]florbetaben* [18F]Florbetaben > [11C]PiB
*Indicates significant difference at p < 0.05 in Bonferroni corrected t-tests.
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USA) applying a special script (developed by Evotec AG,
Hamburg, Germany). This script allows quantitative as-
sessment of the relative plaque load (sum of pixels
representing plaque signals divided by the sum of all
pixels representing the regions of interest). The Texas
Red signal was used by AcapellaTM to correct the TfS
signal for unspecific fluorescence.
Acapella analysis was verified on each section. Minor
detection deficits were tolerated (e.g., failure to detect <5
plaques); larger deficits (e.g., failure to detect a group of
plaques) lead to exclusion of the particular image. In
cases of a large contamination detected as plaque-
specific signal (e.g., a tissue fold or dust particle), the re-
gion of interest was adjusted. At least 8, maximal 12,
sections per tg mouse per staining (respectively 3 to 6
sections per wild-type mouse) were analyzed and mean
values of plaque load calculated per animal. Autoradiog-
raphy (Additional file 1) was performed following proce-
dures already reported [40].
Human [11C]PiB PET
To enable a comparison to human [11C]PiB PET data,
we chose randomly PET datasets from our database of
AD patients and healthy controls at TUM. Subjects la-
belled as AD subjects in this database had a positive PiBFigure 1 Brain uptake of the tested radiopharmaceuticals. Expressed a
at 5 and 30 min post injection (N = 5 for each tracer at each time point). pscan together with measurable cognitive deficits in
neuropsychological testing fulfilling the criteria of de-
mentia. This data had been obtained on a SIEMENS
ECAT HR+ scanner (CTI, Knoxville, TN, USA) accord-
ing to an established and published protocol. Mean glo-
bal cortical PiB uptake relative to cerebellum expressed
as SUVR was calculated in 20 AD patients and in 15
healthy human control subjects using a previously estab-
lished VOI-based approach [48,49].Results
Comparison of fundamental characteristics
[18F]FIBT, [18F]florbetaben, and [11C]PiB were prepared
with comparable high quality, purity, and specific activ-
ities of ≥18 GBq/μmol and directly introduced to a
group of four APP/PS1 and three age-matched ctl mice.
As lipophilicity is an important functional property of a
‘cerebral radiopharmaceutical,’ log Doct/PBS were mea-
sured for [18F]FIBT, [18F]florbetaben, and [11C]PiB
(Table 2). Lipophilicity of FIBT is slightly higher than
those of florbetaben and PiB.
Brain uptake kinetics of florbetaben was measured at 5
and 30 min p.i. in wild-type mice (N ≥ 5) and compared
to already published data for FIBT and PiB [25]
(Figure 1).s percent of injected dose per gram brain weight in male BALB/c mice
.i., post injection.
Figure 2 Visual comparison of the three radiopharmaceuticals within the same group of animals. Each row represents a mean image of
four 24-month-old APP/PS1 transgenic animals (first three rows), respectively, three age matched wild-type animals (C57BL6/J, last three
rows). In vivo PET images in each row represent percentage of injected dose per cubic centimeter (%ID/cc) averaged over 35 to 45 min post
injection, co-registered to a MRI template. From left to right showing axial, sagittal, and coronal views. Red arrow points at higher unspecific
uptake of florbetaben compared to FIBT in the brainstem of wild-type animals.
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in mice
In vivo small animal PET imaging of the three tracers
was compared using a group of four APP/PS1 tg and
three ctl mice, co-registered to the MRI template show-
ing axial, sagittal, and coronal views of group-wise mean
images (Figure 2). Dynamic PET time activity curves of
the cortex-VOI and the cerebellum-VOI for FIBT, florbeta-
ben, and PiB within identical mice are illustrated in
Figure 3. The dynamic PET ratio curves are given in
Figure 4, where tg and ctl mice showed significant differ-
ences in PET. [11C]PiB showed slightly lower initial uptake
values than both 18F-tracers but considerably different
wash-out. More pronounced [11C]PiB washout-out from Aβ-
free regions was resulting in the highest target-to-reference-
region ratios. The lower washout of [18F]florbetabenFigure 3 Dynamic PET time activity curves of the cortex-VOI and the
(rows) within four APP/PS1 tg mice (left column) and three control mice (righ
(%ID/cc) ± SD for a cortex + hippocampus VOI (red line) and a cerebellum VOobserved in BALB/c mice (Figure 1) was also observed on
visual inspection of mean PET images of the control group.
Here, a higher tracer retention of [18F]florbetaben compared
to [18F]FIBT was detected in the brainstem (see red arrow in
Figure 2). Furthermore, mean PET ratios (SUVR, calculated
for time interval 36 to 45 min) for the APP/PS1 tg group
and the control group as well as their ratio SUVRtg/SUVRctl
are given in Table 3. Among the three tracers, [11C]PiB
showed significantly higher unspecific nasal uptake in all
cases. As observed for many PET tracers, all three tracers
showed nonspecific uptake in the retrobulbar space, likely
representing the Harderian gland.
Post mortem plaque load analysis of APP/PS1 and ctl mice
Brain sections of the animals were stained with Thiofla-
vin S for the histological quantification of Aβ plaquecerebellum-VOI. Time-activity curves of the three radiopharmaceuticals
t column). Values are percentage of injected dose per cubic centimeter
I (blue line).
Figure 4 PET ratios and group-wise mean dynamic PET ratio. (A1) PET ratios within the same transgenic animals for FIBT (x-axis) and
florbetaben (y-axis). (A2) Group-wise mean dynamic PET ratio curves for the three radiopharmaceuticals. The four different symbols in A1 mark
the individual transgenic animal for which representative Thioflavin S staining images, and plaque load results are given in (B1) to (B4). White arrows
point at artefacts in the cerebellum that do not represent amyloid plaques.
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ject recognition algorithm [33]. Significant Thioflavin S
positive plaque load was found in each transgenic mouse
(Figure 4B1 to B4). Mean false positive plaque loadTable 3 Mean PET ratios (SUVR ± SD) within the four APP/PS1
Tracer [18F]FIBT
APP/PS1 (N = 4) 1.68 ± 0.15
C57BL6/J (N = 3) 0.95 ± 0.02
tg/ctl 1.78 ± 0.16
p [18F]FIBT > [18F]florbetaben*
The last row gives the statistical results of group comparisons of tg/ctl ratio values;signal was found to be 0.03% (±0.01 SD) in the control
group without amyloid pathology. We found a high lin-
ear association between plaque load and PET ratios for
all three tracers (Figure 5).tg mice and the three control mice (C57BL6/J)
[18F]Florbetaben [11C]PiB
1.35 ± 0.06 2.08 ± 0.24
0.90 ± 0.01 0.99 ± 0.06
1.50 ± 0.06 2.11 ± 0.24
[11C]PiB > [18F]florbetaben* [11C]PiB > [18F]FIBT
*indicates significant difference at p < 0.05 in Bonferroni corrected t-tests.
Figure 5 Association of PET signal to Thioflavin S plaque load.
Lines represent linear regressions for each tracer. The four different
symbols marking the individual transgenic animals are the same as
used in Figure 4.
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To find an expression for the translational value of the
preclinical ranking of the three Aβ radiopharmaceuticals,
a visual association of preclinical and clinical PiB data
was laid out. Figure 6 illustrates the cortical tracer reten-
tion in mice in relation to humans. Analogous to AD pa-
tients, there is a strong uptake of [11C]PiB in cortical
regions and unspecific low uptake in the cerebellum in
transgenic mice. Human controls (HC) and control mice
show only unspecific tracer retention across the whole
brain.
In vivo PiB PET data in AD patients and human con-
trol subjects were also used for calculating SUVR
(Table 4). The SUVR values for [11C]PiB of human AD
patients are comparable to the [11C]PiB ratios found in
our transgenic cohort (2.01 for AD patients vs. 2.08 in
aged APP/PS1 tg mice).
Discussion
This study was motivated by the finding that despite a
considerable number of 18F-labeled Aβ tracers that has
been described, a final answer to the key question, which
of these radiopharmaceuticals shows optimal properties,
cannot be given on the basis of existing data. This is mainly
due to the inhomogeneity of preclinical characterization
methods applied, and further complicated by primarily
ethical, but also financial and other practical restric-
tions of evaluating radiopharmaceuticals head-to-head
in the same human subjects. In addition, it appears
practically impossible to acquire enough preclinical
data to enable a mutual comparison of every possible
pair of tracers. As suggested previously [50], this situ-
ation could be circumvented by using [11C]PiB as com-
mon standard, which is recommendable due to the
considerable body of knowledge already gained for thiscompound. Following this rationale, some of the up-
coming 18F-labeled tracers have been compared to
[11C]PiB [51,52]. Consequently, [11C]PiB PET results
in mice and humans were also implemented in our
study as an anchor point for comparison.
One previous paper compared two 18F-labeled Aβ
tracers indirectly via two separate groups of AD patients
with a [11C]PiB scan as link between the two groups
[29]. However, this type of indirect comparison requires
large cohorts to establish a valid comparison via statis-
tical analysis. In terms of preclinical studies, an intra-
individual based comparison of candidate tracers would
require a direct correlation of the signal with the indi-
vidual plaque load of the animal. This is necessary be-
cause one has to consider that in small animal models of
AD, the inter-subject plaque load is generally not con-
stant, which applies also to our transgenic model [33].
Hence, the most notable advantage of our intra-individual
comparison approach is that it allows for drawing mean-
ingful conclusions from smaller sample sizes (cohorts),
thus resolving some ethical (cf. triple-R rule) and econom-
ical issues at the same time. Furthermore, a group of
transgenic mice can, in principle, be used to compare even
more than three Aβ tracers, which might prove a useful
means of parallel Aβ tracer evaluation in future studies.
Admittedly, a certain drawback of our protocol is that, in
principle, absolute quantification of small animal PET
signals requires complex image analysis steps. However,
by calculating ROI ratios, we chose a straightforward
approach, which is frequently applied in clinical as well
as preclinical settings, and is widely considered to yield
sufficiently precise data to enable meaningful conclu-
sions. The linear association of PET ratios with plaque
load for all three tracers in Figure 5 implies that calcu-
lating ROI ratios further supports this approach. With
the possibility of subsequent ex vivo and histopatho-
logical analyses, the advantages of the preclinical approach
presented here go far beyond merely circumventing
challenges, such as ethical implications of repetitive
scans in clinical studies.
We compared [18F]FIBT with [18F]florbetaben and
[11C]PiB using small animal PET in aged transgenic
APP/PS1 and control mice. The direct head-to-head
PET comparison was supplemented by semi-automated
histological plaque load analyses, using the brain mater-
ial from the animals previously subjected to PET, and by
ex vivo brain uptake kinetic analyses in a separate
group of wild-type BALB/c mice. Pharmacokinetics of
[18F]FIBT was superior to [18F]florbetaben which also re-
sulted in better PET ratios (1.68 ± 0.15 versus 1.35 ±
0.06) in transgenic mice. However, PET ratios of both
tracers correlated equally well with amyloid pathology.
Sufficient uptake in the brain and rapid wash-out of
unbound tracer are important determinants of potential
Figure 6 Direct visual comparison of PiB PET in mice and human. Image is showing from left to right axial, coronal, and sagittal views.
Mouse images represent a mean image of the four APP/PS1 tg mice and the three control mice, respectively. Human images are from a
representative AD patient and healthy control subject, respectively.
Table 4 Human in relation to mouse PET with [11C]PiB
Human Mouse
AD 2.01 ± 0.29 2.08 ± 0.24
Controls 1.22 ± 0.12 0.99 ± 0.06
AD/ctl 1.65 ± 0.41 2.11 ± 0.24
Global cortex/cerebellum ratio (expressed as SUVR) in the human AD group (N
= 20) and the HC group (N = 15) vs. four APP/PS1 tg mice and three
control mice.
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cokinetic properties are commonly assessed by post mor-
tem determination of brain uptake kinetic analyses in
healthy animals. At first glance, chemical properties of
both 18F-labeled tracers meet the requirements for suffi-
cient permeation of the blood-brain barrier, such as low
molecular weight and medium lipophilicity [7]. How-
ever, we noted a lower initial uptake and higher tracer
Yousefi et al. EJNMMI Research  (2015) 5:20 Page 11 of 13retention at 30 min p.i. of [18F]florbetaben compared to
[18F]FIBT in animals without Aβ pathology (BALB/c
mice). Higher initial uptake could be attributed to the
slightly lower lipophilicity of [18F]florbetaben (log D =
1.58 ± 0.13) compared to [18F]FIBT (log D = 1.92 ± 0.06)
[53,54] but might also be related to presence of hydrogen
bond donors and acceptors as well as a higher percentage
of polar surface area. Higher retention of [18F]florbetaben
is likely due to a higher degree of unspecific binding.
Hence, the low amount of unspecific retention of
[18F]FIBT represents a substantial improvement, because
compared to [11C]PiB, most 18F-labeled AD tracers in ad-
vanced clinical trials show a higher tendency towards un-
specific binding to the white matter in humans [52,55].
Comparison of PET images of AD and control mice
indicated higher unspecific binding of [18F]florbetaben
compared to [18F]FIBT, especially in subcortical regions
(red arrow in Figure 2), which is equivalent to a higher
Aβ sensitivity of the latter. This might pose an important
advantage with respect to the potential role of Aβ PET
imaging in the pre-symptomatic phase of the disease
[56], which is considered to begin several years before
symptom onset (accumulation of pathological aggre-
gates), and is likely the favorable time window for anti-
amyloid interventions [57].
Apart from pharmacokinetic properties and specificity
of binding, Aβ affinity and selectivity determines the
quality of a tracer. In a competitive binding assay versus
[3H]PiB, FIBT showed high affinity to Aβ aggregates
(Ki = 2.1 ± 0.8 nM) [25]. Furthermore, in vitro deter-
mination of binding affinities to Aβ aggregates, using
post mortem AD brain homogenates, suggest a higher
Aβ affinity of [18F]FIBT (Kd = 0.7 ± 0.2 nM [28]) than
[18F]florbetaben (Kd = 6.70 ± 0.30 nM, [16]). These re-
sults are nicely corroborated by our in vivo data, as
we found higher tracer retention for [18F]FIBT than
[18F]florbetaben in Aβ-rich brain regions of APP/PS1
transgenic mice (Figure 4A2). Since specific binding of
PiB to Aβ in this mouse model was demonstrated pre-
viously by in vitro, ex vivo, and in vivo experiments
[40], we conclude that higher retention of [18F]FIBT in
target regions corresponds to improved specificity of bind-
ing in vivo as well.
Furthermore, it was shown earlier that the cortex-to-
cerebellum ratios of PiB correlate well with the absolute
amount of Aβ in the cortex, the place where most of the
Aβ deposits are found [41]. Ratios of PiB in APP/PS1
transgenic mice closely resembled the ratios measured
in our cohort of AD patients, further supporting the
notion that our transgenic mouse model is suitable for
PET imaging studies of Aβ pathology. Being aware that
results from small animal experiments can usually not
be directly translated to a clinical setting, we neverthe-
less hold the view that clinical properties of othertracers evaluated in the same setting could be pre-
dicted with certain accuracy. Thus, we assume that
FIBT could perform very well in human as a promising
diagnostic Aβ radiopharmaceutical and robust imaging
tool with potential to become an earlier AD biomarker.
Conclusions
With an increasing number of 18F-labeled Aβ tracers,
comparative studies are of high value for providing
diagnostic and prognostic information and feasibility
rankings. Despite general problems of transferability of
preclinical results to clinical settings, our study sug-
gests that small animal PET imaging using a suitable
animal model combined with ex vivo and in vitro ex-
periments is a practicable approach for comparative Aβ
tracer assessment. Overall, all assessed tracers allowed
high-contrast imaging of Aβ deposits in transgenic models
of AD. Our results indicate a superior performance of
[18F]FIBT relative to [18F]florbetaben regarding pharma-
cokinetics and specific binding affinity towards Aβ
aggregates. These results support further evaluation of
[18F]FIBT in human investigations.
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